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Abbreviations  
 
CI  Confidence Intervals 
FDG-PET/CT 2-[18F]-fluoro-2-deoxy-D-glucose - Positron Emission Tomography/Computed 
Tomography  
FUO  Fever of Unknown Origin 
IQR  Interquartile Range 
IUO  Inflammation of Unknown Origin 
KPI  Key Performance Indicator  
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Introduction 
Fever as an isolated clinical presentation has challenged clinicians for decades1, 2. In 1961 Petersdorf 
and Beeson provided a case definition for ‘fever (or pyrexia) of unknown origin’: 1) a body 
temperature above 38.3°C; 2) on several occasions; with 3) a duration of illness of at least three 
weeks; and 4) no diagnosis within one week of hospital admission2-4. Fifty years on, definitions of 
FUO and the spectrum of aetiologies have evolved, however the diagnostic challenges remain4. FUO 
represents an estimated 2.9% of hospital admissions, with morbidity associated with prolonged 
hospital stay, repeated cycles of invasive investigations and presumptive treatment, mortality rates 
between 12-35%, and cost implications5.   
2-[18F]-fluoro-2-deoxy-D-glucose (FDG)-Positron-Emission-Tomography/Computed-Tomography 
(PET/CT) emerged at the end of the 20th century as an amalgamation between functional and 
conventional anatomical imaging6. Its role in oncological staging has been well-defined, however in 
other specialities there is less clarity7. Specifically, in the investigation of FUO the role of FDG-PET/CT 
in clinical practice and diagnostic algorithms is inconsistent and unestablished. Existing guidelines 
suggest that FDG-PET/CT may be used where conventional investigations have not revealed a 
source8.  
FDG-PET/CT is not associated with nephrotoxicity, and standard protocols expose patients to less 
radiation than a conventional CT. An average FDG-PET/CT scan exposes a patient to 15mSv radiation, 
approximately 5-6 years background radiation, rather than 20-25mSv in a contrast-enhanced chest-
abdomen-pelvis CT. Other advantages include imaging areas (e.g. head and neck, extremities) which 
are beyond the range of most CT scans used in this context, and detection of vascular and truncal 
musculoskeletal inflammation for which cross-sectional contrast CT imaging is insensitive. The main 
caveats are cost and accessibility, FDG-PET/CT costing ₤800, compared to ₤250 for a contrast-
enhanced chest-abdomen-pelvis CT. However this could easily be remunerated by earlier definitive 
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treatment associated with additional diagnostic sensitivity. A marginally reduced length of inpatient 
stay could mitigate the cost, with an average ₤400 for one night hospital admission9.  
Current literature evaluating the role of FDG-PET/CT in FUO is based on observational data involving 
small samples, outdated case definitions, and poor generalisability. Outcomes reported by existing 
meta-analyses focus on sensitivity of FDG-PET/CT in FUO10, 11. Sensitivity refers to the proportion of 
cases with a diagnosis to explain the FUO for which FDG-PET/CT contributed to the diagnosis, or 
A/(A+B) (Table 1). This is statistically inappropriate as there is no reference standard for the 
investigation of FUO to enable estimates of diagnostic accuracy12. In comparison, ‘diagnostic yield’ 
provides a more suitable outcome measure, calculated as the proportion of all FDG-PET/CT scans 
(both normal and abnormal) that contribute to the diagnosis of FUO, A/(A+B+C+D) ( Table 1)13. 
Strikingly, there has been limited analysis of diagnostic yield of FDG-PET/CT beyond that of 
conventional CT. Further, previous meta-analyses have not studied individual patient data. 
 
Table 1   
 
We performed an up-to-date meta-analysis of the diagnostic yield of FDG-PET/CT in all patients with 
FUO. Secondary outcomes included the proportion with an abnormal FDG-PET/CT, final diagnosis, 
false positive results and mortality. The results of the meta-analysis were used to inform two rounds 
of a Delphi survey and a half-day meeting, to develop a consensus on the current knowledge on the 
role of FDG-PET/CT in FUO and inform future research.       
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Materials and Methods 
 
Systematic Review and Meta-analysis 
The protocol was prospectively registered with PROSPERO, an online international database of 
systematic reviews (Study-ID CRD42016032696). It adhered to PRISMA guidelines. QUADAS-2, 
STROBE, Cochrane guidelines and MOOSE guidelines were also utilised14-17.  
Inclusion and Exclusion criteria: All patients were included irrespective of age, comorbidities or 
immunocompromise. Inclusion criteria for FDG-PET/CT protocols were not defined, provided they 
involved a standard [18]-FDG radiotracer. Exclusion criteria were case reports, significant missing 
data such that the primary outcome could not be calculated and non-English studies.  
Search strategy and study detection: See Table 2.  
 
Table 2 
 
Methodological quality assessment: Two authors (TB&AR) independently performed the quality 
assessment and used this to identify studies to be included in the meta-synthesis. Disagreements 
were resolved by a third author (SS). Existing research is restricted to case series and, in the absence 
of comparison with a reference standard, these cannot be interpreted as diagnostic accuracy 
studies. For this reason a specific quality assessment tool was utilised, with nine criteria scored as 
‘High’, ‘Unclear’ or ‘Low’ risk of bias, see Supplement18. Each study is given a quality rating ‘Poor’, 
‘Fair’ and ‘Good’, and quality assessment are summarised in Figure 3. The studies included in the 
inter-rater agreement on the quality assessment is evaluated by a calculated kappa statistic, with 
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95% confidence intervals (CIs) ranging from zero (completely chance-explained agreement) and one 
(perfect agreement)19.  
Data extraction: A data extraction form was developed using Microsoft Excel, see Supplement, and 
two authors (TB&R) independently piloted the form and subsequently performed the data 
extraction. Disagreements were resolved by a third author (SS). Authors of included studies were 
contacted for missing data.   
Analysis: A qualitative synthesis and summary was performed. Results for studies included in the 
quantitative analysis were calculated as proportions, with meta-analysis performed using a random-
effects model in Stata.13 to produce a summary outcome proportion with 95% CIs, and I2 statistic for 
heterogeneity. Sensitivity analyses was performed to exclude poor quality studies. Sub-group 
analyses were performed for immunocompetent adults.    
  
Delphi Consensus 
The Delphi technique is an accepted method for generating consensus in a wide variety of 
disciplines20-22. It involves multiple iteration questionnaire surveys with anonymous and unbiased 
methods. This study included 2-rounds of sequential pre-tested questionnaires, and a half-day face-
face meeting. The working-group included 30 UK-based clinicians with expertise in Epidemiology, 
Research Methods, and Clinical Practice in the specialities of Nuclear Medicine, Radiology, Infectious 
Diseases, Rheumatology, Haematology and General Medicine. The questionnaires were developed, 
refined and administered, each consisting of single and multiple answer questions, free-text 
comments, and 5-point Likert agreement scales. An initial survey was performed in 2015 before the 
face-to-face meeting and consisted of 12 questions. After the meeting, a refined survey with 22 
questions was performed. The surveys and discussion surrounded the current evidence and available 
guidelines, availability of FDG-PET/CT, working case-definitions of FUO, position of FDG-PET/CT in 
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diagnostic algorithms of FUO, and potential factors involved in improving the outcomes in the 
application of FDG-PET/CT. There was also a focus on the future direction of research. Consensus in 
surveys (Supplement) was accepted if agreement (participants responding ‘Strongly agree’ or 
‘Agree’) was over 60%.  
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Results 
 
Systematic review and Meta-analysis 
Study Selection: 22 studies were identified for the qualitative synthesis, and the quality assessment 
selected 18 studies with a total of 905 patients for meta-analysis, see Figure 1. Interrater agreement 
between reviewers was 91% with Kappa 0.85 and P<0.001. Reasons for exclusions are displayed in 
Supplementary Data23-26.  
 
Figure 1 
 
Quality Assessment and Study Design: The qualitative assessment demonstrated a high risk of bias 
across all the included studies, see Figure 2. All the studies were observational case series with no 
comparison group. They were largely (89%) retrospective, involving recruitment from the Nuclear 
Medicine Department databases of patients referred for the indication of a FUO. The studies were 
largely confined to tertiary care centres, and were geographically widely distributed across 15 
different countries in Europe and Asia. The median sample size was 48 (Interquartile range, IQR 24-
74), with a median sample size per year 22 (IQR 8-29). The year of commencement of the studies 
ranged from 2003-2010 (median 2007, IQR 2005-2007), with the year of publication ranging from 
2008-2015 (median 2012, IQR 2010-2013). The median study duration was 35 (IQR 23-49) months. 
There is insufficient data to report the proportion of children. Three studies included children and 
none were exclusively performed in children. 50% of the over-all population was female. 10 (56%) 
studies excluded immunocompromised patients.     
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Figure 2 
 
Case definitions: The included studies largely reported standardised case definitions of FUO as a 
fever for 3 weeks with at least one documented fever over 38’c (17, 94%). There was minimal 
documentation on the duration of symptoms prior to admission or the length of inpatient stay. 
Patients were referred to the nuclear medicine department for FDG-PET/CT at the discretion of the 
responsible clinician. One study mandated discussion at a multidisciplinary meeting prior to referral.  
Intervention: 17 (94%) studies reported details of their FDG-PET/CT protocols. The protocols 
demonstrate the studies utilised the same radiotracer injected at a standard interval of 60-90 mins 
prior to scan. 7 (39%) used IV and/or oral contrast. It was notable that at least 4 (28%) studies 
utilised high-dose CT. One study incorporated a 24 hour carbohydrate restricted diet prior to the 
scan to reduce non-specific cardiac uptake. No studies reported independent assessors interpreting 
the scans, however 7 (39%) reported the involvement of discussion between two assessors, usually a 
nuclear medicine physician and a radiologist. 
Primary outcome: A meta-analysis of 18 studies suggest an overall diagnostic contribution of 56% 
(95% CI 50-61%), I2 61% of FDG-PET/CT in all patients with FUO, illustrated in the forest plot in Figure 
3. Sub-group analysis for diagnostic contribution in 1) adults, 2) immunocompetent patients 
(‘classical FUO’), 3) immunocompetent adults and 4) immunocompetent adults without contrast 
reduced the heterogeneity in the model, however the point estimate of diagnostic yield remained 
largely unchanged, Forest Plots included in Supplementary Data.  
Previous cross-sectional imaging and added contribution of FDG-PET/CT: There were sparse data on 
the documentation or results of previous imaging. Previous investigations were reported in 12 (67%) 
studies, with a median 51% (IQR 27-81%) receiving a CT prior to referral for FDG-PET/CT. Out of 
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these, 5 studies reported the results of previous imaging. A sub-group analysis of these data suggest 
the diagnostic yield of FDG-PET/CT over CT is 32% (95% CI 22-44%), I2 66%.  
 
Figure 3 
 
Secondary outcomes 
Meta-analysis of the proportion with an abnormal FDG-PET/CT produced an overall result of 69% 
(95% CI 63-75%), I2 72. The higher proportion of abnormal scans was accounted for by a proportion 
of ‘false positives’, abnormal scans with no contribution to the final diagnosis, with an overall result 
of 9% (95% CI 5-14%), I2 72. The overall estimate was low which is reassuring but there was striking 
variation across individual studies, between 0 to 33% reported false positive scans.  
73% (95% CI 68-78%) had a final diagnosis, mainly corresponding with three categories: infectious 
diseases representing 30% (95% CI 26-35%), inflammatory causes 20% (95% CI 17-24%) and 
malignancy 13% (95% CI 9-17%), data included in Supplementary Text. Individual patient data 
extraction from 16/18 studies, totalling 749 patients facilitated stratification of diagnoses that did 
and did not benefit from FDG-PET/CT, illustrated in Figures 4-6.  
The presence of raised inflammatory markers were reported in 7 (39%) studies, and there were 
insufficient data to suggest any association with contribution of FDG-PET/CT to diagnosis.  
Methods for the establishment of the final diagnosis were not uniformly reported, however existing 
data suggests a variety of methods including bone marrow, lymph node, tissue biopsy, serology, 
microbiology cultures, immunology and autopsy.  
There were limited data on the period of follow-up and final outcomes of patients. 12 (67%) studies 
reported the length of follow-up, with median 6 (IQR 6-12) months. 
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Figures 4-6 
 
Delphi Consensus 
31/40 (78%) participants responded to the initial Delphi survey. 22/40 (55%) attended the face-to-
face meeting. 30/40 (75%) responded to the second Delphi. The initial Delphi survey consisted of 
three parts aiming to assess 1) availability of FDG-PET/CT for FUO, 2) clinical practice in requesting of 
FDG-PET/CT for FUO, and 3) decision-making in a hypothetical case of FUO, see Supplementary Data 
for the full questionnaire. While 100% reported access to FDG-PET/CT, there was wide-variability in 
reported time from referral to FDG-PET/CT ranging from 2 days to 2 weeks (UK Key Performance 
Indicator, KPI 5 days), and time to reporting of scans ranging from 1 day to 1 week (UK KPI 2days). 
There was widespread agreement (87% responders) that FDG-PET/CT does have a role in the 
investigation of unknown origin (suggested to be 56%), however there was little consensus on sub-
groups or factors that might improve the diagnostic yield. There was also agreement in the value of 
re-assessing patients for developing symptoms and signs, involving other specialities during the 
investigation process, and involvement of nuclear medicine physicians in case discussions. The initial 
survey demonstrated consensus of opinions that false positives needed to be taken into account in 
the decision to refer, that FDG-PET/CT has a high negative predictive value and that false negatives 
may arise due to empirical steroids.  
The face-to-face meeting involved a presentation of the results of the systematic review, meta-
analysis and initial Delphi survey, with sufficient time for questions and discussion. There were 
focussed debate surrounding the case-definition of FUO, investigations required and priority 
outcomes. The meeting identified the variability in access and knowledge of FDG-PET/CT, the 
heterogeneity and updated working definitions of FUO and dearth of evidence but encouraging 
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results in clinical practice. It highlighted the need for clinicians to be aware of the deficits of FDG-
PET/CT: not always imaging the brain, low sensitivity for cardiac and renal tract pathology and 
reduced gastrointestinal uptake with certain medication. In contrast to previous opinions, there is no 
evidence for poor glycaemic control as a contraindication to FDG-PET/CT. Further, the fact that low-
contrast imaging is incorporated into standard protocols does reduce the resolution as compared to 
conventional contrast-CT. It was agreed that certain circumstances affect decision-making, e.g. renal 
impairment, suitability for invasive tests and recent surgery. The meeting concluded with dialogue 
on prospects and feasibility of future research. Current practice incorporates FDG-PET/CT late in 
diagnostic algorithms, however there was acknowledgement that it may have a role as a ‘front-
loaded’ investigation in a subset of patients. This has potential to speed diagnosis, reduced radiation 
exposure and shorten hospital stay, maybe reduce mortality.  
The second Delphi aimed to develop agreement on a case definition of FDG-PET/CT, basic 
investigations required and resolve disagreement to questions. The participants agreed that a febrile 
illness for 2 weeks and without immediate diagnostic clues worked for their practice was a clinically 
acceptable definition. They agreed the definition should incorporate ‘Inflammation of Unknown 
Origin’, IUO, unexplained symptoms for 2 weeks with raised inflammatory markers. Specific 
investigations prior to PET imaging were deemed important, including a cross-sectional CT, TTE and 
specific serology (see supplementary data). However there was also agreement that a front-loaded 
FDG-PET/CT prior to conventional imaging may have a role. There was indecision about whether 
antibiotics should be delayed prior to FDG-PET/CT. Priorities in the outcome of a formal analysis of 
the benefit of front-loaded PET/CT, in the order of importance (most to least important) were 1) 
Time to diagnosis, 2) Time to treatment, 3) Mortality, 4) Side-effects of investigations/ treatment 
and 5) Time to discharge.       
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Conclusion 
PET is a functional imaging tool that provides added information about site and intensity of active 
metabolism, and so unsurprisingly has found its way into the diagnostic pathway of the febrile 
patient. However it is expensive, lacks specificity and needs adequate evidence for its diagnostic 
role. This meta-analysis suggests that a diagnostic yield was achieved in 56% (95% CI 50-61%) 
performed. The results are consistent with previous results of 54% ‘overall helpfulness’ (synonymous 
with diagnostic yield) in a meta-analysis of 10 studies27. Two meta-analyses reviewing sensitivity 
reported 85% (95% CI 81-88%; 15 studies) and 98% (95% CI 94-99%; 9 studies).  
The results are based on results of case series, involving convenience sampling of FUO patients 
referred to Nuclear Medicine departments at the discretion of the responsible physician. Specifically, 
recruitment is not at the point of diagnosis of fever of unknown origin, and there is no control group. 
Patient recruitment may favour patients with renal impairment, poor fitness for invasive biopsies, 
and exclude patients taking metformin, recent surgery or unable to lie still. The room for bias is high 
and these important patient characteristics are poorly documented in the included studies.    
It is also striking that reported diagnostic yield does not address contribution beyond conventional 
imaging as all the patients did not undergo conventional imaging, and reporting of those that did 
was inconsistent. 5 studies included in this meta-analysis reported results of previous imaging. A 
sub-group analysis of these data suggest the diagnostic yield of FDG-PET/CT beyond CT is 32% 
(95%CI 22-44%) with significant heterogeneity (I2 66%).  
Case definitions of FUO adhered to outdated definitions that were established based on minimal 
evidence. It is accepted that subsets of patients do not mount any fever, and for this reason it has 
been suggested that IUO be included in future research. The definition also encompasses an 
extensive list of diagnoses and possibilities, is geographically diverse and limited by resources.  
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FDG-PET/CT is perceived to be an objective intervention. However there is minimal data on inter-
reporter agreement, and none of the studies involved independent reporting by more than one 
radiologist. Importantly the protocols frequently included nephrotoxic contrast, and high dose 
attenuation CTs. Not only may this bias the outcome, but it demonstrates potential risks associated 
with the scans. There is evidence that a special diet to reduce cardiac non-specific cardiac uptake 
may improve outcomes, however the only study that included this protocol did not report cardiac 
diagnoses.   
There is no diagnostic reference standard for FUO, and many patients remain undiagnosed. 
Furthermore there is a level of ambiguity in final diagnoses made by clinicians, and the impression of 
whether the FDG-PET/CT contributed to the diagnosis. In most studies this was based on the result 
of the FDG-PET/CT being compatible with the final diagnosis, however it did not demonstrate a 
diagnostic yield over conventional imaging. Outcome measures need to be relevant to hard patient 
outcomes and to current health systems processes. While sensitivity is not an appropriate outcome 
measure, diagnostic yield may also overestimate the contribution and does not indicate the clinical 
impact of the scan. Other possible outcomes include evaluating time to treatment, discharge or 
mortality.  
It is evident that studies included patients that had not had conventional cross-sectional imaging. 
Furthermore, a referral for FDG-PET/CT was frequently made in spite of pathology identified on 
cross-sectional imaging that could undergo alternative, more specific and objective investigation 
such as a biopsy. With this is mind, the question of diagnostic yield of FDG-PET/CT beyond 
abnormalities detected by cross-sectional imaging is clinically important.  
The individual patient meta-analysis is limited by the low quality of included studies. It does provide 
suggestion of diagnoses that did and did not benefit from FDG-PET/CT, see Figures 4-6. It is rational 
that viral infections, urinary tract infections, bacteraemias and small vessel vasculitides are not easily 
detected on FDG-PET/CT. There are limitations in interpretation of FDG avidity in the brain, heart 
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and urinary tract. The brain and the heart have high glucose uptake and the urinary tract 
concentrates FDG during excreted.   
This study provides a rigorous, updated and balanced insight into current evidence for the role of 
FDG-PET/CT in FUO. It demonstrates a lack of evidence supporting the value and positioning of FDG-
PET/CT in investigative algorithms. The Delphi survey enabled the working group to interpret results 
in line with current practice, and explore directions for research. It highlighted the need for a 
paradigm shift in research, involving prospective studies recruiting at the point of diagnosis of FUO, 
with updated case definitions and hard outcome measures.  While these studies will be a significant 
undertaking with multi-centre collaboration, their completion is vital for balancing both radiation 
exposure and costs against the possible benefits of utilising FDG-PET/CT.  
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Figure and Table Legends 
 
Figure 1: Flow diagram of study selection. 
 
Figure 2: Summary of the Quality Assessment of Included Studies Using the NIH Tool 
 
Figure 3: Diagnostic Yield of FDG-PET/CT in Fever of Unknown Origin (n=18), Proportion 0=0% to 
1=100% +/- 95% CI. The size of the grey box provides a measure of the sample size. I2>50% implies 
moderate heterogeneity.  
 
Figure 4: Infections (n=241; 32% of final diagnosis): Diagnostic yield from PET/CT 
 
Figure 5: Inflammatory/ Autoimmune (n=171; 20% of final diagnosis): Diagnostic yield from PET/CT 
 
Figure 6: Malignancy (n=112; 13% of final diagnoses): Diagnostic yield from PET/CT 
 
Table 1: 2x2 table categorising possible study outcomes.   
 
Table 2: Search Strategy and Study Selection 
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